Abstract
The microbiota in the human gut is strongly correlated with the progression of colorectal cancer (CRC) and with therapeutic responses to CRC. Here, by leveraging the higher concentration of the pro-tumoural Fusobacterium nucleatum and the absence of antineoplastic butyrate-producing bacteria in the faecal microbiota of patients with CRC, we show that—in mice with orthotopic colorectal tumours or with spontaneously formed colorectal tumours—oral or intravenous administration of irinotecan-loaded dextran nanoparticles covalently linked to azide-modified phages that inhibit the growth of F. nucleatum significantly augments the efficiency of first-line chemotherapy treatments of CRC. We also show that oral administration of the phage-guided irinotecan-loaded nanoparticles in piglets led to negligible changes in haemocyte counts, immunoglobulin and histamine levels, and liver and renal functions. Phage-guided nanotechnology for the modulation of the gut microbiota might inspire new approaches for the treatment of CRC.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Chemical reaction-mediated covalent localization of bacteria
Nature Communications Open Access 17 December 2022
-
Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry
Signal Transduction and Targeted Therapy Open Access 02 December 2022
-
A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea
Nature Communications Open Access 19 April 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$79.00 per year
only $6.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout





Data availability
The authors declare that the main data that support the results of this study are available within the paper and the Supplementary Information. The raw and analysed datasets generated during the study are available for research purposes from the corresponding author on reasonable request.
References
Tremaroli, V. & Bäckhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 489, 242–249 (2012).
Schroeder, B. & Bäckhed, F. Signals from the gut microbiota to distant organs in physiology and disease. Nat. Med. 22, 1079–1089 (2016).
Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science 336, 1262–1267 (2012).
van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
Dewint, P. et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial. Gut 63, 292–299 (2014).
Vieira, S. M. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 359, 1156–1161 (2018).
Wang, Z. N. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
Sears, C. L. & Garrett, W. S. Microbes, microbiota, and colon cancer. Cell Host Microbe 15, 317–328 (2014).
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).
Zheng, D. W. et al. Optically-controlled bacterial metabolite for cancer therapy. Nat. Commun. 9, 1680 (2018).
Fan, J. X. et al. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration. Nano Lett. 18, 2373–2380 (2018).
Louis, P., Hold, G. L. & Flint, H. J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12, 661–672 (2014).
Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013).
Mima, K. et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1, 653–661 (2015).
Yu, T. C. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548–563 (2017).
Singh, N. et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40, 128–139 (2014).
Cani, P. D. & Jordan, B. F. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat. Rev. Gastroenterol. Hepatol. 15, 671–682 (2018).
Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017).
Kelly, C. J. et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17, 662–671 (2015).
Agarwal, R. et al. Inhaled bacteriophage-loaded polymeric microparticles ameliorate acute lung infections. Nat. Biomed. Eng. 2, 841–849 (2018).
Citorik, R. J., Mimee, M. & Lu, T. K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32, 1141–1145 (2014).
Hussain, S. et al. Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy. Nat. Biomed. Eng. 2, 95–103 (2018).
Maslowski, K. M. & Mackay, C. R. Diet, gut microbiota and immune responses. Nat. Immunol. 12, 5–9 (2011).
Wang, H. et al. Selective in vivo metabolic cell-labeling-mediated cancer targeting. Nat. Chem. Biol. 13, 415–424 (2017).
Yu, J. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 66, 70–78 (2017).
Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120–123 (2012).
Wu, L. N. et al. Sensitive and selective bacterial detection using tetracysteine-tagged phages in conjunction with biarsenical dye. Angew. Chem. Int. Ed. 50, 5873–5877 (2011).
Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195–206 (2013).
Sui, X. et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 4, e838 (2013).
Metch, J. W. et al. Metagenomic analysis of microbial communities yields insight into impacts of nanoparticle design. Nat. Nanotechnol. 13, 253–259 (2018).
Liang, X. et al. Self-assembly of an amphiphilic Janus camptothecin-floxuridine conjugate into liposome-like nanocapsules for more efficacious combination chemotherapy in cancer. Adv. Mater. 29, 1703135 (2017).
Pang, X. Y. et al. Inter-species transplantation of gut microbiota from human to pigs. ISME J. 1, 156–162 (2007).
Stempler, O. et al. Interspecies nutrient extraction and toxin delivery between bacteria. Nat. Commun. 8, 315 (2017).
Ritsma, L. et al. Surgical implantation of an abdominal imaging window for intravital microscopy. Nat. Protoc. 8, 583–594 (2013).
Heijink, D. M. et al. Total abdominal 18F-FDG uptake reflects intestinal adenoma burden in Apc mutant mice. J. Nucl. Med. 52, 431–436 (2011).
Acknowledgements
This work was supported by the National Natural Science Foundation of China (grant nos. 51690152, 51533006 and 51833007).
Author information
Authors and Affiliations
Contributions
D.-W.Z. and X.-Z.Z. conceived the project and designed the experiments. X.D. and D.-W.Z. synthesized materials. P.P and K.-W.C. performed in vitro microbiological experiments. X.D. performed in vitro cell experiments. D.-W.Z., X.D. and J.-X.F. collected and analysed the data. X.D., P.P. and K.-W.C. performed in vivo experiments. D.-W.Z., X.D., S.-X.C. and X.-Z.Z. co-wrote the manuscript. All of the authors discussed the results and reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Methods, Supplementary Figs. 1–17 and Supplementary Tables 1–6.
Rights and permissions
About this article
Cite this article
Zheng, DW., Dong, X., Pan, P. et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat Biomed Eng 3, 717–728 (2019). https://doi.org/10.1038/s41551-019-0423-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-019-0423-2
This article is cited by
-
Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry
Signal Transduction and Targeted Therapy (2022)
-
Targeting the gut microbiota for cancer therapy
Nature Reviews Cancer (2022)
-
A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea
Nature Communications (2022)
-
Chemical reaction-mediated covalent localization of bacteria
Nature Communications (2022)
-
Bacteriophages and their potential for treatment of gastrointestinal diseases
Nature Reviews Gastroenterology & Hepatology (2022)